TEM
BEARISH
$56.78
Live
Tempus AI, Inc. · NASDAQ
Target $72.4
(+27.5%)
$41.67
52W Range
$104.32
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$10.19B
P/E
N/A
ROE
-89.5%
Profit margin
-19.3%
Debt/Equity
2.7
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Tempus AI exhibits critical financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across profitability and operational efficiency. While the company demonstrates explosive revenue growth of 83% YoY, this is offset by deep negative margins and a high Debt/Equity ratio of 2.70. The bearish outlook is further reinforced by aggressive insider selling, including significant divestments by the CEO and CFO, and a technical trend score of 0/100. Despite analyst optimism, the fundamental health metrics suggest a high-risk profile.
Key Strengths
Exceptional YoY revenue growth of 83.00%
Strong Q/Q revenue growth of 82.98%
Healthy liquidity with a Current Ratio of 3.13
High Gross Margin of 62.74% indicating a scalable core product
Positive analyst sentiment with a target price of $72.40
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Heavy insider selling totaling $43.97M with zero insider buys
High leverage with a Debt/Equity ratio of 2.70
Significant valuation premium (Price/Book of 20.58)
Deeply negative Forward P/E (-628.03) indicating a long path to profitability
AI Fair Value Estimate
Based on comprehensive analysis
$48.5
-14.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
15
85
40
10
0
AI Verdict
High-Risk Growth Speculation
Key drivers: Hyper-growth revenue, Severe fundamental weakness, Insider divestment
Confidence
90%
Value
15/100
Trades at a massive premium to book value with no current earnings to support the valuation.
Positives
No standout positives identified.
Watchpoints
- P/B of 20.58 is excessive
- P/S of 8.01 is high for negative margin company
- No Graham Number due to lack of earnings
Future
85/100
Growth rates are top-tier, but monetization efficiency remains unproven.
Positives
- 83% YoY Revenue Growth
- Strong Q/Q momentum
- Operating in high-growth Health AI sector
Watchpoints
- Uncertainty regarding the timeline to positive net income
Past
40/100
Historical performance shows a pattern of 'growth at any cost' with significant price volatility.
Positives
- Consistent revenue acceleration
Watchpoints
- 6-month price decline of 38.6%
- Consistent quarterly losses
Health
10/100
The Piotroski score is a primary red flag, indicating systemic financial instability.
Positives
- Strong Current Ratio (3.13)
Watchpoints
- Piotroski F-Score 1/9
- Debt/Equity 2.70
- Negative ROE of -89.48%
Dividend
0/100
Company is in a growth phase and cannot support dividends.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$56.78
Analyst Target
$72.4
Upside/Downside
+27.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TEM and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TEM
Tempus AI, Inc.
Primary
|
+41.1% | +41.1% | +38.6% | -38.6% | +20.9% | +23.5% |
|
BIO-B
Bio-Rad Laboratories, Inc.
Peer
|
-47.0% | -22.7% | -10.4% | +26.6% | +0.7% | +0.7% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
|
TECH
Bio-Techne Corporation
Peer
|
-41.6% | -26.4% | +28.2% | -2.9% | +17.7% | +5.3% |
|
AXSM
Axsome Therapeutics, Inc.
Peer
|
+146.1% | +162.6% | +79.0% | +84.4% | +21.0% | +4.9% |
TEM
Tempus AI, Inc.
Primary
5Y
+41.1%
3Y
+41.1%
1Y
+38.6%
6M
-38.6%
1M
+20.9%
1W
+23.5%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-47.0%
3Y
-22.7%
1Y
-10.4%
6M
+26.6%
1M
+0.7%
1W
+0.7%
BMR
BioMarin Pharmaceutical Inc.
Peer
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
TEC
Bio-Techne Corporation
Peer
5Y
-41.6%
3Y
-26.4%
1Y
+28.2%
6M
-2.9%
1M
+17.7%
1W
+5.3%
AXS
Axsome Therapeutics, Inc.
Peer
5Y
+146.1%
3Y
+162.6%
1Y
+79.0%
6M
+84.4%
1M
+21.0%
1W
+4.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-628.03
PEG Ratio
N/A
P/B Ratio
20.58
P/S Ratio
8.01
EV/Revenue
8.43
EV/EBITDA
-62.52
Market Cap
$10.19B
Profitability
Profit margins and return metrics
Profit Margin
-19.27%
Operating Margin
-16.7%
Gross Margin
62.74%
ROE
-89.48%
ROA
-9.66%
Growth
Revenue and earnings growth rates
Revenue Growth
+83.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+82.98%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.7
High debt
Current Ratio
3.13
Strong
Quick Ratio
2.88
Excellent
Cash/Share
$4.22
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
64.7%
Op. Margin
-16.7%
Net Margin
-14.8%
Total Assets
$2.3B
Liabilities
$1.8B
Equity
$0.5B
Debt/Equity
3.63x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
117%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$-0.04
+22.1% surprise
2025-11-04
$-0.46
-8.9% surprise
2025-08-08
$-0.22
+13.0% surprise
Healthcare Sector Comparison
Comparing TEM against 498 companies in the Healthcare sector
(28 bullish, 153 neutral, 317 bearish)
Return on Equity (ROE)
-89.48%
This Stock
vs
-95.47%
Sector Avg
-6.3%
(Below Avg)
Profit Margin
-19.27%
This Stock
vs
-15.87%
Sector Avg
+21.4%
(Superior)
Debt to Equity
2.7
This Stock
vs
2.89
Sector Avg
-6.5%
(Lower)
Revenue Growth
83.0%
This Stock
vs
137.48%
Sector Avg
-39.6%
(Slower)
Current Ratio
3.13
This Stock
vs
4.66
Sector Avg
-32.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TEM
Tempus AI, Inc.
|
BEARISH | $10.19B | - | -89.5% | -19.3% | $56.78 | |
|
BIO-B
Bio-Rad Laboratories, Inc.
|
BEARISH | $9.79B | - | -9.5% | -26.4% | $312.75 | Compare |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | Compare |
|
TECH
Bio-Techne Corporation
|
NEUTRAL | $9.48B | 114.3 | 4.0% | 6.7% | $60.58 | Compare |
|
AXSM
Axsome Therapeutics, Inc.
|
BEARISH | $9.37B | - | -275.5% | -40.9% | $185.96 | Compare |
TEM
Tempus AI, Inc.
BEARISH
Mkt Cap
$10.2B
P/E
-
ROE
-89.5%
Price
$56.78
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | LEFKOFSKY ERIC PAUL | Chief Executive Officer | Sale | 166,250 | $7,711,150 |
| 2026-03-02 | EPSTEIN DAVID R | Director | Sale | 250 | $12,672 |
| 2026-03-02 | ROGERS JAMES WILLIAM | Chief Financial Officer | Sale | 11,414 | $578,576 |
| 2026-02-20 | LEFKOFSKY ERIC PAUL | Chief Executive Officer | Stock Award | 263,430 | - |
| 2026-02-20 | BARTOLUCCI RYAN M | Officer | Stock Award | 12,998 | - |
| 2026-02-20 | FUKUSHIMA RYAN | Officer | Stock Award | 74,993 | - |
| 2026-02-20 | ROGERS JAMES WILLIAM | Chief Financial Officer | Stock Award | 37,496 | - |
| 2026-02-20 | POLOVIN ANDREW | Officer | Stock Award | 38,420 | - |
| 2026-02-20 | POLOVIN ANDREW | Officer | Sale | 19,092 | $1,141,136 |
| 2026-02-19 | LEFKOFSKY ERIC PAUL | Chief Executive Officer | Sale | 179,837 | $10,589,918 |
| 2026-02-19 | BARTOLUCCI RYAN M | Officer | Sale | 2,902 | $171,363 |
| 2026-02-19 | FUKUSHIMA RYAN | Officer | Sale | 9,592 | $566,408 |
| 2026-02-19 | ROGERS JAMES WILLIAM | Chief Financial Officer | Sale | 10,084 | $595,460 |
| 2026-02-19 | PHELPS ERIK J. | Officer | Sale | 9,464 | $562,472 |
| 2026-02-02 | EPSTEIN DAVID R | Director | Sale | 370 | $21,982 |
LEFKOFSKY ERIC PAUL
Chief Executive Officer
2026-03-26
166,250 shares
·
$7,711,150
EPSTEIN DAVID R
Director
2026-03-02
250 shares
·
$12,672
ROGERS JAMES WILLIAM
Chief Financial Officer
2026-03-02
11,414 shares
·
$578,576
LEFKOFSKY ERIC PAUL
Chief Executive Officer
2026-02-20
263,430 shares
BARTOLUCCI RYAN M
Officer
2026-02-20
12,998 shares
FUKUSHIMA RYAN
Officer
2026-02-20
74,993 shares
ROGERS JAMES WILLIAM
Chief Financial Officer
2026-02-20
37,496 shares
POLOVIN ANDREW
Officer
2026-02-20
38,420 shares
POLOVIN ANDREW
Officer
2026-02-20
19,092 shares
·
$1,141,136
LEFKOFSKY ERIC PAUL
Chief Executive Officer
2026-02-19
179,837 shares
·
$10,589,918
BARTOLUCCI RYAN M
Officer
2026-02-19
2,902 shares
·
$171,363
FUKUSHIMA RYAN
Officer
2026-02-19
9,592 shares
·
$566,408
ROGERS JAMES WILLIAM
Chief Financial Officer
2026-02-19
10,084 shares
·
$595,460
PHELPS ERIK J.
Officer
2026-02-19
9,464 shares
·
$562,472
EPSTEIN DAVID R
Director
2026-02-02
370 shares
·
$21,982
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
8-K
10-Q
8-K
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
15 analysts
Jefferies
2026-04-13
Underperform
Guggenheim
2026-03-30
Buy
Buy
Needham
2026-03-11
Buy
Buy
HC Wainwright & Co.
2026-03-09
Buy
Buy
Morgan Stanley
2026-03-03
Overweight
Overweight
JP Morgan
2026-02-25
Neutral
Neutral
Needham
2026-02-25
Buy
Buy
BTIG
2026-02-25
Buy
Buy
Mizuho
2026-02-19
Outperform
Baird
2026-02-17
Outperform
Past News Coverage
Recent headlines mentioning TEM from our newsroom.
Newest → oldest
No matching news yet.